patient view
This page is a research summary built from public sources (FDA, NIH, clinical trial registries). It is not medical advice.Always talk to your doctor about treatment decisions. Drug information here may be incomplete or out of date — verify with your prescriber and the manufacturer's package insert.
drug · antibody
ravulizumab LA
Marketedupdated 2mo agoby Alexion Pharmaceuticals Inc🔗 ChEMBL
Approvedannual revenue · 2024–2024peak $3.9B
community read0 votes
Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for hemolytic-uremic syndrome and paroxysmal nocturnal hemoglobinuria and 11 investigational indications.
targets
Complement C5
all catalysts(0)
nothing on the calendar yet
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that